



Retraction: Neoadjuvant Therapy for Esophageal Adenocarcinoma in the Community Setting—Practice and Outcomes

OPEN ACCESS

Approved by:

Giuseppe Giaccone,
Georgetown University, United States

*Correspondence:

Frontiers Editorial Office
editorial.office@frontiersin.org

Specialty section:

This article was submitted to
Gastrointestinal Cancers,
a section of the journal
Frontiers in Oncology

Received: 10 April 2019

Accepted: 10 April 2019

Published: 24 April 2019

Citation:

Frontiers Editorial Office (2019)
Retraction: Neoadjuvant Therapy for
Esophageal Adenocarcinoma in the
Community Setting—Practice and
Outcomes. *Front. Oncol.* 9:324.
doi: 10.3389/fonc.2019.00324

Frontiers Editorial Office*

A Retraction of the Original Research Article

Neoadjuvant Therapy for Esophageal Adenocarcinoma in the Community Setting—Practice and Outcomes

by Abdo, J., Bertellotti, C. A., Cornell, D. L., Agrawal, D. K., and Mittal, S. K. (2017). *Front. Oncol.* 7:151. doi: 10.3389/fonc.2017.00151

The journal retracts the 18 July 2017 article cited above.

During a recent review by the Creighton University Institutional Review Board that approved this study, it was found that the authors utilized and included some datasets that were not IRB-approved. Therefore, the study did not receive full ethics committee approval and is being withdrawn.

The authors concur with the retraction and sincerely regret any inconvenience this may have caused to the reviewers, editors, and readers of Frontiers in Oncology.

Copyright © 2019 Frontiers Editorial Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.